Services

testing cytokine targeting

The search for compounds that target pro-inflammatory mediators is of ever increasing importance to treat various diseases such osteoarthritis or psoriasis.

Using relevant and standardizable human telomerized cell lines, Evercyte offers services for testing compounds for a potency to reduce the release of certain pro-inflammatory cytokines.

General information

In vitro model: Evercyte´s in vitro bioassays to test compounds for a potential to alter cytokine release are based on human telomerized cells from different tissues and organs (e.g. skin, cornea, lung, vascular system, kidney, placenta).

Assay set-up: treatment of telomerized cells with compounds followed by measurement of cytokine release using different methods such as western blotting, ELISA or Luminex.
Timelines:
depending on the number of compounds to be tested, the number of replicates and concentrations requested, it takes between 3 and 6 weeks to deliver results.

Testing the response of fibroblasts to Interleukin-17A treatment

release of Interleukin-6 upon Interleukin-17A treatment

Treatment of human dermal fibroblasts (fHDF/TERT166) with Interleukin-17A (IL17A) results in expression of Interleukin-6 (IL6) in a concentration dependent manner. This model system therefore allows screening for compounds that inhibit the cellular response to IL17A and subsequently counteract the pro-inflammatory activity of IL17A and tissue inflammation.

Print Friendly, PDF & Email
get in contact

Related Services

testing the potency of extracellular vesicles / exosomes

read more

fHDF/TERT166

telomerized human foreskin fibroblasts

read more

MSCs for production of clinical grade extracellular vesicles

send us specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

all about our
EV cell factories

read more

fHDF/TERT166 cells

human telomerized fibroblasts responding to interleukin-17A (IL17A) or transforming growth factor ß (TGFß) treatment

read more

Related Services

testing functional properties of extracellular vesicles / exosomes

specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email